Bhavana Pothuri

Aug 27, 2024 | medscape.com | Ursula Matulonis |Bhavana Pothuri

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Ursula A. Matulonis, MD: I'm Dr Ursula Matulonis. Welcome to season 1 of the Medscape InDiscussion: Endometrial Cancer podcast series. Today we'll discuss health disparities in the diagnosis and treatment of endometrial cancer. First, let me introduce my esteemed guest, Dr Bhavana Pothuri.

Aug 18, 2024 | targetedonc.com | Bhavana Pothuri

A retrospective study analyzed treatment patterns and outcomes for patients with advanced endometrial cancer. While mismatch repair (MMR) and microsatellite instability (MSI) testing has become standard, its use in guiding treatment decisions varies. Patients with MMR-deficient (dMMR) tumors had longer treatment-free periods compared to those with MMR-proficient (pMMR). However, the use of newer, targeted therapies based on MMR/MSI status is still suboptimal.

Jun 27, 2024 | onclive.com | Bhavana Pothuri

Bhavana Pothuri, MD, gynecologic oncologist, professor, Department of Obstetrics and Gynecology, New York University (NYU) School of Medicine, director, gynecologic oncology clinical trials, NYU Langone Health, discusses real-world treatment patterns and outcomes in patients with advanced endometrial cancer according to mismatch repair (MMR) and microsatellite instability (MSI) status.

Dec 4, 2023 | onclive.com | Ritu Salani |Bhavana Pothuri

Diversity and Access to Clinical Trials in Endometrial CancerExperts Ritu Salani, MD, MBA, and Bhavana Pothuri, MD, explore the significance of enrolling diverse patients in clinical trials and the pivotal role of community settings in advancing endometrial cancer research and treatment.

Dec 4, 2023 | onclive.com | Ritu Salani |Bhavana Pothuri

Delve into the exciting developments in endometrial cancer treatment, including HER2 antibody drug conjugates, checkpoint inhibitors, and the promising impact of these therapies in the quest to reduce chemotherapy use.